Rebecca E. Mercer - Concepedia

Author

Rebecca E. Mercer

Canadian Centre for Applied Research in Cancer Control ORCID

Also Known As

Mercer, Rebecca, Mercer, Rebecca E, R. MERCER, R. Mercer, R.E. MERCER, R.E. Mercer, Rebecca E Mercer, Rebecca E. Mercer, Rebecca Mercer

Publications

754

Citations

H-Index

Concepts

All Affiliations

Canadian Centre for Applied Research in Cancer Control University of Toronto Health Sciences Centre Cancer Care Ontario Sunnybrook Health Science Centre

About

Rebecca E. Mercer is an author at Canadian Centre for Applied Research in Cancer Control specializing in public health, public health policy, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Public Health	3	3	121
2	Medicine	2	2	33
3	Health Policy	2	2	33
4	Natural Sciences	1	1	88
5	Biology	1	1	88

Rebecca E. Mercer

Publications

503

Citations

H-Index

Page 1

	Year	Citations
Loss of Magel2, a Candidate Gene for Features of Prader-Willi Syndrome, Impairs Reproductive Function in Mice Rebecca E. Mercer, Rachel Wevrick PLoS ONE	2009	99
Regionally reduced brain volume, altered serotonin neurochemistry, and abnormal behavior in mice null for the circadian rhythm output gene <i>Magel2</i> Rebecca E. Mercer, Erin M. Kwolek, Jocelyn M. Bischof, American Journal of Medical Genetics Part B Neuropsychiatric Genetics	2009	99
ADAPTIVE SEARCH USING A REPRODUCTIVE META‐PLAN Rebecca E. Mercer, J.R. SAMPSON Kybernetes Search OptimizationAdaptive SystemsBiologyReproductive SuccessEvolution Strategy	1978	88
Magel2 Is Required for Leptin-Mediated Depolarization of POMC Neurons in the Hypothalamic Arcuate Nucleus in Mice Rebecca E. Mercer, Sheldon D. Michaelson, Melissa J. Chee, PLoS Genetics	2013	78
Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration Kelvin Chan, Seungree Nam, Bill Evans, BMJ Open	2020	52
Cost and value of cancer medicines in a single-payer public health system in Ontario, Canada: a cross-sectional study Joseph C. Del Paggio, Rohini Naipaul, Scott Gavura, The Lancet Oncology OncologyHealthcare ValueHealth PolicyHealth EconomicsCancer Medicines	2024	19
Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration’s Reassessment and Uptake Working Group Wei Fang Dai, Vanessa Sarah Arciero, Erica Craig, Current Oncology Preclinical TherapeuticsCancer ManagementClinical SpecialtiesPharmacotherapyCanadian Real-world Evidence	2021	14
Comparative Effectiveness and Safety of Pertuzumab and Trastuzumab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy for Treatment of Metastatic Breast Cancer Wei Fang Dai, Jaclyn Beca, Chenthila Nagamuthu, JAMA Network Open	2022	13
Building a National Reassessment Process for Oncology Drugs: Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration through a Simulated Reassessment Exercise Wei Fang Dai, Erica Craig, Brent Fraser, Current Oncology	2021	11
Are We Making a Difference? A Qualitative Study of Patient Engagement at the pan-Canadian Oncology Drug Review: Perspectives of Patient Groups Rebecca E. Mercer, Alexandra Chambers, Helen Mai, Value in Health	2020	10

Page 1